| SERINC3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | SERINC3, AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1, serine incorporator 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 607165 MGI: 1349457 HomoloGene: 38230 GeneCards: SERINC3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Serine incorporator 3 is a protein that in humans is encoded by the SERINC3 gene.[5][6] It has been demonstrated that SERINC3 acts as a retrovirus restriction factor. [7][8][9]
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000132824 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000017707 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ Bossolasco M, Lebel M, Lemieux N, Mes-Masson AM (November 1999). "The human TDE gene homologue: localization to 20q13.1-13.3 and variable expression in human tumor cell lines and tissue". Molecular Carcinogenesis. 26 (3): 189–200. doi:10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T. PMID 10559794. S2CID 19505445.
- ↑ "Entrez Gene: SERINC3 serine incorporator 3".
- ↑ Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, et al. (October 2015). "HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation". Nature. 526 (7572): 212–7. Bibcode:2015Natur.526..212R. doi:10.1038/nature15399. PMC 4861059. PMID 26416734.
- ↑ Chande A, Cuccurullo EC, Rosa A, Ziglio S, Carpenter S, Pizzato M (November 2016). "S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3". Proceedings of the National Academy of Sciences of the United States of America. 113 (46): 13197–13202. doi:10.1073/pnas.1612044113. PMC 5135340. PMID 27803322.
- ↑ Ramdas P, Bhardwaj V, Singh A, Vijay N, Chande A (2020-02-24). "Coevolution of retroviruses with SERINCs following whole-genome duplication divergence". bioRxiv. doi:10.1101/2020.02.24.962506.
{{cite journal}}: CS1 maint: overridden setting (link)
Further reading
- Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee NH, et al. (September 1995). "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence" (PDF). Nature. 377 (6547 Suppl): 3–174. PMID 7566098.
- Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Bonaldo MF, Lennon G, Soares MB (September 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Bossolasco M, Veillette F, Bertrand R, Mes-Masson AM (August 2006). "Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis". Oncogene. 25 (33): 4549–58. doi:10.1038/sj.onc.1209488. PMID 16547497. S2CID 24696947.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.